Amylyx Pharmaceuticals Inc (AMLX)
1.76
-0.02
(-1.12%)
USD |
NASDAQ |
Apr 26, 16:00
1.755
0.00 (0.00%)
Pre-Market: 20:00
Amylyx Pharmaceuticals Cash from Financing (TTM): 3.543M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.543M |
| September 30, 2023 | 235.48M |
| June 30, 2023 | 234.59M |
| March 31, 2023 | 232.37M |
| December 31, 2022 | 431.79M |
| Date | Value |
|---|---|
| September 30, 2022 | 198.56M |
| June 30, 2022 | 330.21M |
| March 31, 2022 | 333.03M |
| December 31, 2021 | 158.51M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
3.543M
Minimum
Dec 2023
431.79M
Maximum
Dec 2022
239.79M
Average
234.59M
Median
Jun 2023
Cash from Financing (TTM) Benchmarks
| Cassava Sciences Inc | 2.56M |
| iRhythm Technologies Inc | 8.82M |
| Bristol-Myers Squibb Co | 8.278B |
| Moderna Inc | -1.377B |
| ACADIA Pharmaceuticals Inc | 25.13M |